Opdivo plus chemotherapy improved median OS to 14.4 months versus 11.1 months in patients with PD-L1 CPS ≥5. The 5-year OS rates were 16% for Opdivo plus chemotherapy and 6% for chemotherapy alone in ...
CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus ...
GABRP as a biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer (WJOG10417GTR study). Co-expressing pattern of multiple biomakers and dynamic change of Claudin18.2 ...
Hair loss is one of the most common and emotionally challenging side effects of chemotherapy, affecting self-esteem, identity, and social confidence. Known as chemotherapy-induced alopecia (CIA), it ...
Erdafitinib is a pan–fibroblast growth factor receptor (FGFR) inhibitor approved for the treatment of locally advanced or metastatic urothelial carcinoma in adults with susceptible FGFR3/2 alterations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results